IL-6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study
- PMID: 38376135
- PMCID: PMC11664450
- DOI: 10.1111/jdv.19898
IL-6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study
Abstract
Background: Systemic inflammation is considered a major player in the pathogenesis of epidermolysis bullosa (EB), but its pattern has only been described in small heterogeneous cohorts. There is controversy if and how systemic inflammation should be therapeutically targeted.
Methods: We examined serum proinflammatory, anti-inflammatory, and itch related cytokines in a paediatric cohort of 29 patients with junctional and dystrophic EB. The cytokine that emerged as the most relevant was measured in a validation cohort of 42 patients during follow-up visits over 2 years.
Results: IL-6 showed the most consistent and highest aberration dominating systemic inflammation. IL-6 correlated with wound body surface area (BSA) in both, finding and validation cohorts. Patients with less than 3% wound BSA had normal IL-6, while IL-6 levels significantly increased at more than 5% and 10% of wound BSA. TGF-β was only marginally elevated in patients with severe recessive dystrophic EB, while TNF-α, IFN-γ and IL-1β varied inconsistently. Patients reporting itch showed elevations in type 2 immunity (IgE, TSLP, IL4 and/or IL-31, respectively).
Conclusions: Our data suggest a dominant skin barrier and wound healing inflammatory pattern in junctional and dystrophic EB that depends on the wound area and not on the EB type. In EB, itch mediators may be similar to other pruritic disorders.
© 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Autoimmunity and Cytokine Imbalance in Inherited Epidermolysis Bullosa.Int J Mol Sci. 2016 Sep 24;17(10):1625. doi: 10.3390/ijms17101625. Int J Mol Sci. 2016. PMID: 27669234 Free PMC article.
-
Mechanism underlying pruritus in recessive dystrophic epidermolysis bullosa: Role of interleukin-31 from mast cells and macrophages.J Eur Acad Dermatol Venereol. 2024 May;38(5):895-903. doi: 10.1111/jdv.19738. Epub 2023 Dec 12. J Eur Acad Dermatol Venereol. 2024. PMID: 38084871
-
The eye in epidermolysis bullosa.Br J Ophthalmol. 1999 Mar;83(3):323-6. doi: 10.1136/bjo.83.3.323. Br J Ophthalmol. 1999. PMID: 10365041 Free PMC article.
-
Epidermolysis Bullosa: Pediatric Perspectives.Curr Pediatr Rev. 2022;18(3):182-190. doi: 10.2174/1573396317666210525161252. Curr Pediatr Rev. 2022. PMID: 34036913 Review.
-
[Syndromes 13. Epidermolysis bullosa].Ned Tijdschr Tandheelkd. 1999 Aug;106(8):302-5. Ned Tijdschr Tandheelkd. 1999. PMID: 11930425 Review. Dutch.
Cited by
-
Unveiling the value of C-reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study.Exp Dermatol. 2024 Aug;33(8):e15146. doi: 10.1111/exd.15146. Exp Dermatol. 2024. PMID: 39075828 Free PMC article.
-
Prevalence and Mechanisms of Itch in Chronic Wounds: A Narrative Review.J Clin Med. 2025 Apr 22;14(9):2877. doi: 10.3390/jcm14092877. J Clin Med. 2025. PMID: 40363908 Free PMC article. Review.
-
Interplay between iron metabolism, inflammation, and EPO-ERFE-hepcidin axis in RDEB-associated chronic anemia.Blood Adv. 2025 May 13;9(9):2321-2335. doi: 10.1182/bloodadvances.2024015271. Blood Adv. 2025. PMID: 40036737 Free PMC article.
-
Systems immunology integrates the complex endotypes of recessive dystrophic epidermolysis bullosa.Nat Commun. 2025 Jan 14;16(1):664. doi: 10.1038/s41467-025-55934-7. Nat Commun. 2025. PMID: 39809737 Free PMC article.
References
-
- Reimer‐Taschenbrecker A, Künstner A, Hirose M, Hübner S, Gewert S, Ibrahim S, et al. Predominance of Staphylococcus correlates with wound burden and disease activity in dystrophic epidermolysis bullosa: a prospective case‐control study. J Invest Dermatol. 2022;142:2117–2127.e8. - PubMed
-
- Tampoia M, Abbracciavento L, Morrone M, Fumarulo R. IL‐6/IL‐10 ratio as a prognostic and predictive marker of the severity of inherited epidermolysis bullosa. Iran J Immunol. 2017;14:340–349. - PubMed
-
- Onoufriadis A, Proudfoot LE, Ainali C, Torre D, Papanikolaou M, Rayinda T, et al. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing. Exp Dermatol. 2022;31:420–426. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials